CD133+/Flk-1+ cells (circulating EPCs) in patients with sepsis as compared to healthy controls. For quantification of peripheral circulating EPCs, all myelomonocytic cells were gated (A). Gated cells were analyzed without antibody staining (B), using the isotype control (C), and with Flk-1 FITC and CD133 (+secondary antibody) combined. Circulating EPCs in all patients suffering from sepsis and in sepsis patients within the 'high creatinine group' were significantly higher than in healthy controls. There was no statistically significant difference in EPCs between healthy controls and patients within the 'normal creatinine group'. (Results as mean ± SEM).